Clinical Research Directory
Browse clinical research sites, groups, and studies.
Prophylaxis of Complications of Basic Therapy Using Naderin in Socially Significant Diseases
Sponsor: MIPO Clinic
Summary
This interventional study evaluated the efficacy of Naderin (sodium nucleinate) for the prophylaxis of complications during basic therapy and medical rehabilitation in patients with socially significant diseases, including malignant neoplasms, tuberculosis, and hepatitis C. The study assessed the immunocorrective effects of Naderin on hematological parameters, the incidence of infectious complications, and clinical outcomes. A total of 75 patients (40 in the main group and 35 in the control group) were enrolled. Patients in the main group received Naderin as an adjunct to standard therapy, while the control group received standard therapy without immunocorrection. The study demonstrated that Naderin reduced the duration of neutropenia by 4-5 days, attenuated the decline in white blood cell and lymphocyte counts during chemotherapy, and reduced the incidence of treatment interruptions due to complications. These findings suggest that Naderin may serve as an effective immunomodulatory agent for supportive care in patients with socially significant diseases.
Official title: Prophylaxis of Complications of Basic Therapy and Medical Rehabilitation Using Naderin in Socially Significant Diseases, Including Malignant Neoplasms, Tuberculosis, and Hepatitis C
Key Details
Gender
All
Age Range
18 Years - 50 Years
Study Type
INTERVENTIONAL
Enrollment
75
Start Date
2013-05-15
Completion Date
2014-03-12
Last Updated
2026-06-26
Healthy Volunteers
No
Interventions
Naderin
Naderin (sodium nucleinate) is an immunomodulatory agent administered as an adjunct to standard basic therapy for the prophylaxis of complications. It enhances immune function, reduces the duration of neutropenia, and attenuates the decline in hematological parameters during chemotherapy and other aggressive therapies.
Standard Therapy
Standard basic therapy according to clinical protocols for malignant neoplasms, tuberculosis, and hepatitis C. Includes chemotherapy, anti-tuberculosis therapy, and antiviral therapy as per national guidelines.